Detailed performance report for EXPONENT INC covering Q3 2026. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.
Summary of Financial Performance: Exponent delivered a strong Q3 2026, with total revenue up 18% year over year to $173.7M and net revenue up 12% to $153.1M. Net income rose 10% to $30.9M, and diluted EPS increased 16% to $0.64. EBITDA grew 16% to $45.0M, with margin expanding to 29.4% of net revenue from 28.3% last year. Utilization improved to 76.7% and realized rates increased about 4%. Growth was driven by broad-based demand, especially user research and dispute/failure analysis work. Stock buybacks reduced diluted shares by about 5% year over year.
Company Outlook & Strategy: Management raised full-year 2026 guidance, now expecting net revenue growth of 10% to 11% and EBITDA margin of 28.0% to 28.3%. For Q4, the company expects net revenue growth of 8% to 10% and EBITDA margin of 26.3% to 26.8%. The company reiterated its strategy of investing in talent, expanding capabilities, and leveraging its integrated engineering/science platform to address increasingly complex, high-consequence client problems. Management stressed confidence in long-term sustainable growth.
Key Industry Trends: Exponent highlighted the convergence of technology, infrastructure, and human behavior as a major market driver. AI is increasingly moving into the physical world, creating demand for testing, validation, explainability, and failure analysis. Strong demand was noted in data centers, advanced transportation, wearable/health technologies, and chemicals of concern. Regulatory scrutiny, safety expectations, and litigation risk are rising across these areas.
Operational Highlights: Engineering and Other Scientific segment net revenue rose 13% and accounted for 85% of net revenue, driven by user research, sensory perception, and dispute-related work in consumer products, chemicals, and transportation. Environmental and Health segment grew 3%, supported by projects assessing chemical effects on human health and the environment. Hiring remains a priority, with focus on human factors, biomechanics, thermal science, polymers, metallurgy, energy storage, and senior talent in Environmental and Health. Capex is expected at $10M to $12M for 2026.
Challenges & Risks: Management noted that growth in Environmental and Health is currently slower than the core engineering business, though they are investing to accelerate it. Q4 utilization is expected to decline seasonally due to holidays and vacations. The company also faces complexity and uncertainty tied to rapid AI adoption, evolving regulation, product safety issues, and dispute/litigation exposure. Compensation and infrastructure investments remain elevated, though viewed as necessary to support growth.
Key Analyst Questions & Responses: Analysts asked about the strong Q3 utilization; management said it reflected broad-based demand rather than calendar effects, with little downside from the one large project that stepped down less than expected. On AI, management said AI-related work is already meaningful, estimated at 15% to 20% of business, and growing across both proactive and reactive engagements, especially in transportation, data centers, and medical devices. Analysts also asked about headcount and pricing; management said recruiting is being ramped up across several specialties and that pricing/headcount plans will be addressed further in future planning. On capital allocation, management reaffirmed a stable policy: continue dividends, opportunistic buybacks, and selective small acquisitions if attractive.
Access the official earnings call transcript for EXPONENT-INC 2026 Q3. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.